Entyvio (Wave 1) | LaunchTrends | US | 2014

Takeda’s Entyvio (vedolizumab) gained FDA approval in May 2014; the drug launched in the United States in June 2014. This report measures the impact of this novel agent on the moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) market following launch. The report evaluates physicians’ current awareness and familiarity with Entyvio, the advantages and disadvantages compared to currently available therapies, and the current and anticipated usage of the drug; as well as the drug’s promotional activity.

launch Related Market Assessment Reports